Literature DB >> 17660987

Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Eriko Akaza1, Mitsuko Yuzawa, Yoko Matsumoto, Shiho Kashiwakura, Kyoko Fujita, Ryusaburo Mori.   

Abstract

PURPOSE: To determine the efficacy of photodynamic therapy (PDT) with verteporfin for polypoidal choroidal vasculopathy (PCV).
METHODS: PDT was performed in 35 patients (35 eyes) with PCV. We evaluated the number of treatments and compared visual acuity (VA), ophthalmological findings, and changes in polypoidal lesions and branching vascular networks by measuring lesion diameters using Heidelberg retina angiography before PDT, and then every 3 months for 1 year after PDT.
RESULTS: The mean annual number of treatment sessions was 2.2. VA was improved or maintained in 80% of the patients. Retinal pigment epithelium detachment, retinal detachment, hemorrhage, and/or exudates disappeared in 69%, and leakage resolved in 74% of the patients. Polypoidal lesions disappeared completely on indocyanine green angiography in 83% of the patients. All branching vascular networks persisted. Polypoidal lesions had recurred at the termini of the remaining branching vascular networks at 9 months after the first PDT in two eyes and at 12 months in one eye.
CONCLUSIONS: PDT with verteporfin for PCV appears to improve or maintain VA for the first posttreatment year. Approximately 70% of PCV cases showed improved ophthalmoscopic findings. However, as polypoidal lesions recur after PDT in some cases, further study is needed to confirm the long-term efficacy of PDT for PCV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17660987     DOI: 10.1007/s10384-007-0452-3

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  12 in total

1.  A study of laser photocoagulation for polypoidal choroidal vasculopathy.

Authors:  Mitsuko Yuzawa; Ryuzaburo Mori; Miho Haruyama
Journal:  Jpn J Ophthalmol       Date:  2003 Jul-Aug       Impact factor: 2.447

2.  [Criteria for diagnosis of polypoidal choroidal vasculopathy].

Authors: 
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2005-07

3.  Photodynamic therapy with verteporfin for peripapillary choroidal neovascularization.

Authors:  Brett J Rosenblatt; Gaurav K Shah; Kevin Blinder
Journal:  Retina       Date:  2005-01       Impact factor: 4.256

4.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

5.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

6.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Nazimul Hussain; Anjli Hussain; Sundaram Natarajan
Journal:  Indian J Ophthalmol       Date:  2005-06       Impact factor: 1.848

7.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

8.  Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.

Authors:  Wai-Man Chan; Dennis S C Lam; Timothy Y Y Lai; David T L Liu; Kenneth K W Li; Yi Yao; Tak-Hung Wong
Journal:  Ophthalmology       Date:  2004-08       Impact factor: 12.079

9.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

Review 10.  Photodynamic therapy in macular diseases of asian populations: when East meets West.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Yasuo Tano; David T L Liu; Kenneth K W Li; Dennis S C Lam
Journal:  Jpn J Ophthalmol       Date:  2006 Mar-Apr       Impact factor: 2.211

View more
  32 in total

1.  Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-21       Impact factor: 3.117

2.  Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.

Authors:  Kenji Yamashiro; Akitaka Tsujikawa; Akihiro Nishida; Michiko Mandai; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

3.  Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy.

Authors:  M Inoue; A Arakawa; S Yamane; K Kadonosono
Journal:  Eye (Lond)       Date:  2013-08-23       Impact factor: 3.775

4.  Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.

Authors:  Ryusaburo Mori; Mitsuko Yuzawa; Zeon Lee; Miho Haruyama; Eriko Akaza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-30       Impact factor: 3.117

5.  Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2011-02-18       Impact factor: 2.447

6.  Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up.

Authors:  Akiko Miki; Shigeru Honda; Hiroshi Kojima; Masaya Nishizaki; Tomoko Nagai; Masashi Fujihara; Mamoru Uenishi; Mihori Kita; Yasuo Kurimoto; Akira Negi
Journal:  Jpn J Ophthalmol       Date:  2013-03-19       Impact factor: 2.447

Review 7.  Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.

Authors:  Yamini Sahu; Niharika Chaudhary; Mukesh Joshi; Aastha Gandhi
Journal:  Int Ophthalmol       Date:  2020-10-20       Impact factor: 2.031

8.  Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

Authors:  Shigeki Machida; Tomoharu Nishimura; Kunifusa Tamada; Tomomi Harada; Daijiro Kurosaka
Journal:  Doc Ophthalmol       Date:  2011-12-31       Impact factor: 2.379

9.  Photodynamic therapy for polypoidal choroidal vasculopathy: baseline perimetric results and visual outcomes.

Authors:  Mitsuhiro Imasawa; Toyoaki Tsumura; Arata Sekine; Toyohiko Kikuchi; Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

10.  Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration.

Authors:  Koko Saito; Teiko Yamamoto; Daijiro Tsuchiya; Ryo Kawasaki; Shion Haneda; Hidetoshi Yamashita
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.